Surovatamig  (Synonyms: AZD0486; TNB-486)

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma^[1][2].

half-G4-kappa_VH-h-CH2-CH3

Human IgG4 (S228P) kappa, Isotype Control

Human

CD3D & CD3E & CD19

Surovatamig specifically binds to CD19⁺ human B cell lines with an EC₅₀ range of 1.2-5.2 nM and a cell surface K_d of 1.8 nM on Nalm6 cells^[1].
Surovatamig (24 h) activates human CD4⁺ and CD8⁺ T cells in the presence of CD19⁺ RI-1 tumor cells, with EC₅₀ values of 103.6 pM and 121.8 pM, respectively^[1].
Surovatamig (5 day) induces proliferation of human CD4⁺ and CD8⁺ T cells in the presence of CD19⁺ RI-1 tumor cells, with EC₅₀ values of 62.9 pM and 46.9 pM, respectively^[1].
Surovatamig (0.0001-100 nM；48 h) triggers the release of cytotoxic granules (perforin and granzyme B) from human T cells in the presence of CD19⁺ RI-1 tumor cells^[1].
Surovatamig (24-96 h) induces time-dependent lysis of primary human B cells via T cell redirection, with >90% lysis by 96 h and an EC₅₀ range of 0.93-1.35 nM^[1].
Surovatamig (48 h) induces concentration-dependent, CD19-specific lysis of multiple human B-NHL/ALL cell lines via both CD4⁺ and CD8⁺ T cell redirection, with EC₅₀ values of 23.5 ± 11.5 pM (Raji) and 0.9 ± 0.2 nM (RI-1)^[1].
Surovatamig (48 h) induces potent CD19-specific tumor cell lysis with significantly lower levels of proinflammatory cytokines (IL-2, IFNγ, TNF) and higher cytokine release EC₅₀ values^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Surovatamig (10 ng-10 μg/mouse; i.v.; every 5 days; 3 doses) induces dose-dependent tumor reduction and clearance in a disseminated Burkitt lymphoma xenograft model^[1].
Surovatamig (1-100 μg/mouse; i.v.; every 4 days; 6 doses) induces dose-dependent tumor growth inhibition in a subcutaneous diffuse large B-cell lymphoma xenograft model, with the 100 μg/mouse dose achieving 88.52% tumor growth inhibition by day 40 post-implantation^[1].
Surovatamig (0.4 mg/kg) delivers potent anti-tumor activity while inducing significantly reduced CRS-associated systemic cytokine release in a humanized disseminated DLBCL xenograft model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

915  [NCBI] & 916  [NCBI] & 930  [NCBI] & 21790  [NCBI]

P04234 & P07766 & P15391

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

110.46 kDa

2892667-02-4

Liquid

Colorless to light yellow

[Surovatamig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  half-G4-kappa_VH-h-CH2-CH3

• 
  Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Surovatamig. The EC₅₀ for this effect is 893.5 ng/mL.
• 
  Immobilized CD3D-CD3E Heterodimer Protein, Human (Biotinylated, HEK293, His, HY-P700677) can bind Surovatamig. The EC₅₀ for this effect is 909.9 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ Juakat cells with Surovatamig (HY-P991028, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Malik-Chaudhry HK, et al. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. MAbs. 2021;13(1):1890411.  [Content Brief]

  [2]. Lin W, et al. Pre-clinical evaluation of surovatamig (AZD0486) in comparison to CD20xCD3 bispecific antibodies[J]. 2025.